List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for the given year is not complete until April of the following year. Annual Reports data is a snapshot of agency reported information for that year and hence might look different from the live data in the Awards Information charts.

  1. Topic 378: Symptomatic Toxicity Mobile Monitor (SympTMM)

    SBC: Vivonics, Inc.            Topic: NCI

    The goal of this NIH Phase I SBIR proposal is to develop and validate a new method to monitor the symptomatic toxicities and health-related quality of life of cancer patients who are undergoing and have undergone radiation therapy during the course of their treatment. The proposal is built around expertise in mobile application development (Vivonics Inc.) and radiation oncology (Dr. TJ Fitzgerald ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Topic 378: PRORAD- A Mobile Application for Patient Related Outcomes of Radiotherapy

    SBC: Charles River Analytics, Inc.            Topic: NCI

    Cancer patients receiving radiation therapy experience toxic side effects of the radiation, and sensitivity to radiation is variable across both patients and tumors, and is poorly understood. This Phase I SBIR project aims to design and demonstrate the feasibility of a Patient Reported Outcome mobile application for surveillance of RADiotherapy toxicity (PRORAD) that integrates NIH's Patient Repor ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Topic 374: Sustained Delivery of PARP Inhibitors for Cancer Chemoprevention

    SBC: TheraNano LLC            Topic: NCI

    Here we propose to study two injectable formulations that provide different delivery routes for Talazoparib, potent PAPR inhibitor: An implant, InCeT-Talazoparib, which can be injected directly in the tumor where it will act as a sustained release depot of Talazoparib over a prolonged period of approximately 30 days. It delivers 100% of the drug to the tumor site with almost no systemic toxicity. ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Topic 343- Cognitive Assessment and Monitoring Platform For Integrative Research (CAMPFIRE II)

    SBC: Charles River Analytics, Inc.            Topic: NCI

    Cancer survivors commonly report cognitive impairments following chemotherapy. With a growing number of cancer survivors comes an increased urgency to better understand the precise etiology and prevalence of cognitive changes associated with cancer and cancer treatment. This pursuit is impeded by a lack of assessment tools that can accurately detect the full scope of cognitive deficits. To address ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. System for the Spec. of Acute THC Imp. Using Val. Alg.

    SBC: Charles River Analytics, Inc.            Topic: NIDA

    NIH through NIDA solicits the research and development of digital markers for detection of marijuana intoxication and cognitive impairmentIn this Project the ContractorCharles River Analyticsin partnership with the SubcontractorMcLean Hospitalproposes to design and demonstrate a prototype system for the Specification of Acute THC Impairment using Validated AlgorithmsSATIVASATIVAingests data across ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Measure of Dysfunctional Retinal Ganglion Cell Response

    SBC: Valenti, Denise            Topic: NIDA

    NIH through NIDA solicits the research and development of digital markers for detection of marijuana intoxication and cognitive impairmentIn this project the Contractor will develop and clinically validate a technology that indirectly tests retinal ganglion cell functionThe sensory psychomotor signal in the smartphone application named IMMAD is a visual field test using a small square with stripes ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Reagents for Immunologic Analysis of Non-mammalian Models

    SBC: Protein Innovation Labs, Inc.            Topic: NIAID

    The zebrafish is as an extraordinary model organism that provides unique opportunities for probing vertebrate biologywith direct implications for human physiology and diseaseThere exists a significant need to enhance and broaden the utility of this model with the development of new tools and strategiesNotablyantibodies are available for fewer thanof theknown zebrafish proteinsand the majority of t ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. The purpose of this contract is to evaluate and modulate the molecular pathways involved in regulating and enhancing HIV envelope/antigen expression in mammalian cell lines and to accelerate development of purification platforms in a cGMP manufacturing se

    SBC: Anatagen Pharmaceuticals, Inc.            Topic: NIAID

    HIVthe virus that causes AIDSis one of the world s most serious health and development challengesAccording to UNAIDSthere were approximatelymillion people worldwide living with HIV AIDS at the end ofThe vast majority of people living with HIV are in lowto middle income countriesparticularly in sub Saharan AfricaA low cost vaccine is the preferred response to protect the human populationHoweverdesp ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. The purpose of this contract is to develop an assay to detect minor populations of resistant variants in blood specimens from HIV-infected individuals with HIV RNA viral loads above 1000 copies/ml

    SBC: ALDATU BIOSCIENCES, INC.            Topic: NIAID

    Antiretroviral therapyARTreduces mortality and morbidity in HIV infected individualsbut specific HIV mutationsDRMsare associated with resistanceIt is now known that certain DRMs can contribute to virological failure even at very low concentrationsbut standard tests are inadequately sensitive to detect these minor variantsMethods to detect minor variants that contribute to HIV virological failure a ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Recombinant Outer Membrane Vesicles as a Novel Adjuvant for a Malaria Vaccine

    SBC: VERSATOPE THERAPEUTICS, INC.            Topic: NIAID

    Plasmodium falciparum is the most fatal species of the malaria protozoan parasite infecting humansThe ability to control disease or outbreaks of Pfalciparum malaria with a vaccine has eluded investigators for decadesInnovative adjuvants for malaria vaccines are urgently needed to provide long lasting immune responses and high levels of inhibitory antibodiesWe propose to develop a novel malaria vac ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government